As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma

Urovant began life as an offshoot of Vivek Ramaswamy’s Roivant goliath, but is now firmly a part of the Sumitovant Biopharma family after the life science company bought up the rest of its shares in the biotech.

This comes around a month before Urovant’s PDUFA fate with the FDA for its lead asset vibegron, which it hopes to market as a rival to Astellas’ overactive bladder disorder (OAB) med Myrbetriq.